Stock IOBT IO BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

IO Biotech, Inc. Stock

Equities

IOBT

US4497781090

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
1.47 USD +2.08% Intraday chart for IO Biotech, Inc. -2.65% -21.81%
Apr. 15 IO Biotech Announces Marjan Shamsaei as Senior Vice President CI
Apr. 09 IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103 CI

Financials (USD)

Sales 2024 * - Sales 2025 * 1.5M Capitalization 94.87M
Net income 2024 * -105M Net income 2025 * -130M EV / Sales 2024 * -
Net cash position 2024 * 36.5M Net cash position 2025 * 265M EV / Sales 2025 * -114 x
P/E ratio 2024 *
-1.04 x
P/E ratio 2025 *
-1.05 x
Employees 68
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.05%
More Fundamentals * Assessed data

Chart IO Biotech, Inc.

Dynamic Chart

Latest news about IO Biotech, Inc.

IO Biotech Announces Marjan Shamsaei as Senior Vice President CI
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103 CI
IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer CI
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting CI
IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IO Biotech Doses First Patient in Phase 2 Trial of Melanoma Treatment MT
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial CI
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
IO Biotech Appoints Helen Collins, Md, to Its Board of Directors CI
IO Biotech Completes Enrollment in Pivotal Phase 3 Trial in Advanced Melanoma MT
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma CI
IO Biotech Says Non-Small Cell Lung Cancer Therapy Showed Partial Response in More Than Half of Evaluable Patients MT
IO Biotech, Inc. Announces Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology Congress CI
Piper Sandler Starts IO Biotech at Overweight MT
More news

Latest transcript on IO Biotech, Inc.

Logo IO Biotech, Inc.
IO Biotech, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 04:15 PM
More transcripts

Analyst Recommendations on IO Biotech, Inc.

Piper Sandler Starts IO Biotech at Overweight MT
Morgan Stanley Adjusts Price Target on IO Biotech to $7 From $11, Maintains Overweight Rating MT
Morgan Stanley Adjusts Price Target on IO Biotech to $11 From $15, Maintains Overweight Rating MT
HC Wainwright Initiates IO Biotech With Buy Rating, Sets $10 Price Target MT
Morgan Stanley Adjusts IO Biotech's Price Target to $15 from $21, Keeps Overweight Rating MT
More recommendations

Press releases IO Biotech, Inc.

IO Biotech : Corporate Deck April 2024 PU
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness AQ
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 AQ
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer AQ
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting AQ
More press releases

Quotes and Performance

1 day+2.08%
1 week-2.65%
Current month-15.03%
1 month-15.03%
3 months-18.78%
6 months+50.31%
Current year-21.81%
More quotes

Highs and lows

1 week
1.41
Extreme 1.41
1.57
1 month
1.41
Extreme 1.41
1.85
Current year
1.41
Extreme 1.41
2.10
1 year
0.82
Extreme 0.8163
2.64
3 years
0.82
Extreme 0.8163
17.88
5 years
0.82
Extreme 0.8163
17.88
10 years
0.82
Extreme 0.8163
17.88
More quotes

Managers and Directors - IO Biotech, Inc.

Managers TitleAgeSince
Mai-Britt Zocca FOU
 Founder 56 14-11-30
Amy Sullivan DFI
 Director of Finance/CFO 54 22-10-14
Eric Faulkner CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
David Smith BRD
 Director/Board Member 64 22-02-28
K. Hirth CHM
 Chairman 72 16-08-31
Kathleen Glaub BRD
 Director/Board Member 70 18-04-30
More insiders

Quotes

Date Price Change Volume
24-04-23 1.47 +2.08% 58 974
24-04-22 1.44 -2.70% 78,243
24-04-19 1.48 +0.68% 91,570
24-04-18 1.47 -2.00% 178,237
24-04-17 1.5 -0.66% 36,501

Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT

More quotes

Company Profile

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company's product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech's lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Sector
Biotechnology & Medical Research
Calendar
2024-05-12 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.44 USD
Average target price
8.75 USD
Spread / Average Target
+507.64%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IO BIOTECH, INC. Stock IO Biotech, Inc.
-21.81% 94.87M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 40.08B
MODERNA, INC. Stock Moderna, Inc.
+8.49% 40B
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 26.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 24.58B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 11.94B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 11.66B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.01B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IOBT Stock